<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15002">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230126</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-0443</org_study_id>
    <secondary_id>NCI-2011-03221</secondary_id>
    <nct_id>NCT00230126</nct_id>
  </id_info>
  <brief_title>OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Randomized Study of OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miguel Villalona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determines tumor response rate, time to tumor progression and survival rate at 1
      year produced by OSI-774 in previously treated African American patients with nonsmall cell
      lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Researchers are seeking to identify treatment regimens with low toxicity for
      non-small cell lung cancer (NSCLC), especially for African Americans with this disease who
      seem to have a larger burden of comorbidities and decreased performance status. The current
      study uses a drug called OSI-774 in previously treated African American patients with NSCLC.
      OSI-774 is a targeted agent designed as an EGFR tyrosine kinase inhibitor. Previous research
      indicates that tumor cells overexpress EGFR receptors, and this drug works by blocking these
      receptors on tumor cells that that help them grow.

      OSI-774 is FDA approved for the treatment of patients with non-small cell lung cancer that
      had been previously treated with chemotherapy. Unfortunately, very little data exist in the
      pharmacokinetics and metabolism of EGFR blockers in African Americans and in the assessment
      of how efficacious these agents are in this patient group. Yet, research suggests that EGFR
      blockage may have a greater impact on this patient population. Since the development of skin
      rash following therapy with EGFR blockers may be a surrogate of obtaining sufficient
      concentrations at the tissue level and potential efficacy, the current study is a randomized
      phase II trial designed to compare normal dose levels of OSI-774 with dose levels determined
      by body weight and with subsequent amounts adjusted further into the study to generate a
      skin rash. Through the current study, researchers are testing their theory that this dosing
      method will increase the number of patients with effective tissue concentrations and result
      in an increase in patient responses.

      Purpose: The primary objective of this study is to determine the objective tumor response
      rate, the time to tumor progression, and the survival rate at one year produced by OSI-774
      in previously treated African American patients with advanced NSCLC. A second objective is
      to evaluate if a regimen of single agent OSI-774, with dosing initially influenced by body
      weight and with subsequent titration to achieve skin rash is a suitable regimen for future
      studies of this agent. A third objective is to measure if changes in EGFR from tumor and
      blood cells correlate with the development of rash and clinical benefit. The
      pharmacokinetics of OSI-774 will also be characterized through study participants.

      Treatment: Patients in this study will be given OSI-774. A computer will randomly assign
      patients into one of two treatment groups. Group one will be given a standard dose of
      OSI-774. The dose of OSI-774 will not be increased in group one. However, patients in group
      one will have the dose level decreased due to unacceptable side effects. Group two will
      receive OSI-774 at a dose modified to their body weight at study entry and subsequently
      adjusted further into the study to generate a skin rash. For all study participants, OSI-774
      will be administered daily in oral pills. Several tests and exams will be given throughout
      the study to closely monitor patients. Treatments will be discontinued due to disease growth
      or unacceptable side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease Control Rate at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>no progression of disease at 12 weeks from starting treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Every 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year Survival Rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>A erlotinib 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>erlotinib 150 mg/day cycles 1 - 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B erlotinib modified according to weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
    <arm_group_label>A erlotinib 150 mg</arm_group_label>
    <arm_group_label>B erlotinib modified according to weight</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have histologically or cytologically confirmed stage IIIB or IV NSCLC treated
             with 1-2 platinum- or taxane-containing regimens

          -  Measurable disease

          -  May have had prior surgery &amp; external beam radiation

          -  African American

          -  18 years or older

        Exclusion Criteria:

          -  Known brain mets

          -  Prior treatment with EGFR targeting therapies

          -  Pregnant/lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Villalona, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 4, 2014</lastchanged_date>
  <firstreceived_date>September 28, 2005</firstreceived_date>
  <firstreceived_results_date>April 15, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Miguel Villalona</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>African Americans</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Erlotinib 150 mg/Day</title>
          <description>150 mg/day cycles 1 - 3
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Erlotinib 150 to 200 mg/Day Depending on Body Weight; C</title>
          <description>Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to generate skin rash.
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Fifty-eight patients . 31 men, 24 women.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: 150 mg/Day</title>
          <description>150 mg/day
erlotinib: Arm A: 150 mg/day Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Cycle 1 - 150-200 mg/Day Depending on Body Weight</title>
          <description>Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to generate skin rash.
Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63" lower_limit="29" upper_limit="83"/>
                <measurement group_id="B2" value="59" lower_limit="37" upper_limit="96"/>
                <measurement group_id="B3" value="62" lower_limit="29" upper_limit="96"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Control Rate at 12 Weeks</title>
        <description>no progression of disease at 12 weeks from starting treatment</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib: Arm A: 150 mg/Day Cycles 1 - 3.</title>
            <description>150 mg/day cycles 1 - 3
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Cycle 1 - 175 or 200 mg/Day Depending on Body Weight; C</title>
            <description>Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to generate skin rash.
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Disease Control Rate at 12 Weeks</title>
            <description>no progression of disease at 12 weeks from starting treatment</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression</title>
        <time_frame>Every 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>A Erlotinib 150 mg/Day Cycles 1 - 3</title>
            <description>erlotinib 150 mg/day cycles 1 - 3
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>B Erlotinib Cycle 1 Dose Modified According to Weight</title>
            <description>erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Progression</title>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.8" lower_limit="2.5" upper_limit="3.1"/>
                  <measurement group_id="O2" value="2.4" lower_limit="1.5" upper_limit="2.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>1-year Survival Rate</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>A Erlotinib 150 mg/Day Cycles 1 - 3</title>
            <description>erlotinib 150 mg/day cycles 1 - 3
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>B Erlotinib Cycle 1 Dose Modified According to Weight</title>
            <description>erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>1-year Survival Rate</title>
            <units>percentage of patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: 150 mg/Day Cycles 1 - 3</title>
          <description>150 mg/day cycles 1 - 3
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Cycle 1 - 175 or 200 mg/Day Depending on Body Weight; C</title>
          <description>Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to generate skin rash.
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>anorexia</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomitting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <description>not severe</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Miguel Villalona</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>614-366-5068</phone>
      <email>miguel.villalona@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
